- Home
- JBDI vs KPRX Comparison
JBDI vs KPRX Comparison
Compare JBDI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | KPRX |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 11.7M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JBDI | KPRX |
|---|---|---|
| Price | $1.38 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 39.3K | 13.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $1.76 |
| 52 Week High | $2.28 | $2.95 |
Technical Indicators
Market Signals| Indicator | JBDI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 59.97 |
| Support Level | $1.13 | $2.44 |
| Resistance Level | $1.41 | $2.72 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 72.73 | 90.91 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.